Outlook Therapeutics operates as a clinical-stage biopharmaceutical enterprise dedicated to developing and commercializing monoclonal antibody treatments for various back-of-the-eye ophthalmic conditions. Its primary commercial focus centers on advancing its proprietary formulation of bevacizumab, designed to provide safe, effective, and FDA-approved alternative therapies for patients suffering from retinal diseases such as wet age-related macular degeneration.